Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of UK-390,957 in adult men with premature ejaculation
2004-003737-13Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UK-390957 in premature ejaculation (PE), sponsored by Pfizer. Primary endpoint: Primary: Safety and tolerability of UK-390,957 up to 52 weeks. Started Oct 2004; status: completed.
02
Drugs
UK-390957
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on 2004-003737-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003737-13.